News Release 

Allergic reactions including anaphylaxis after receipt of 1st dose of Pfizer-BioNTech COVID-19 Vaccine

JAMA

Research News

What The Study Did:
This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the Centers for Disease Control and Prevention in the first week of use of the Pfizer-BioNTech COVID-19 vaccine in the United States.

Authors: 
Tom Shimabukuro, M.D., M.P.H., M.B.A., of the CDC in Atlanta, is the corresponding author.

To access the embargoed study:  
Visit our For The Media website at this link
https://media.jamanetwork.com/

(doi:10.1001/jama.2021.0600)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

###

Media advisory:
The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article 
This link will be live at the embargo time
https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2021.0600?guestAccessKey=b5738d71-4ef0-48c0-9130-d675e62d1fa8&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=012121

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.